Latest

2 stories

Hide weekly roundups

Friday, September 18

Electra Therapeutics prices $350 million IPO, sets Nasdaq listing under ETRA

The late-stage biopharma sold 23,333,334 shares at $15.00 each ahead of a September 21, 2026 closing, funding its lead sHLH antibody through a Phase 2/3 registrational trial.

SEC filing

Friday, August 28

FinancingElectra Therapeutics Inc.

Electra Therapeutics files for IPO to fund lead antibody in blood disorder sHLH

The clinical-stage biotech seeks Nasdaq listing under "ETRA" as it advances ipsoprubart through a global registrational trial after strong early Phase 1b results.

SEC filing